Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2019

Open Access 01-12-2019 | Short report

A comparison of nurses’ and physicians’ perception of cancer treatment burden based on reported adverse events

Authors: Shing M. Lee, Jieling Miao, Ruby Wu, Joseph M. Unger, Ken Cheung, Dawn L. Hershman

Published in: Health and Quality of Life Outcomes | Issue 1/2019

Login to get access

Abstract

Background

Cancer treatments are associated with a multitude of adverse events (AEs). While both nurses and physicians are involved in patient care delivery and AE assessment, very few studies have examined the differences between nurses’ and physicians’ reporting and perception of AEs. An approach was recently proposed to assess treatment burden based on reported AEs from the physician’s perspective. In this paper, we use this approach to evaluate nurses’ perception of burden, and compare nurses’ and physicians’ assessment of the overall and relative burden of AEs.

Methods

AE records for 334 cancer patients from a randomized clinical trial conducted by the SWOG Cancer Research Network were evaluated by 14 nurses at Columbia University Medical Center. Two nurses were randomly selected to assign a burden score from 0 to 10 based on their impression of the global burden of the captured AEs. These nurses did not interact directly with the patients. Scores were compared to previously obtained physicians scores using paired T-test and Kappa statistic. Severity scores for individual AEs were obtained using mixed-effects models with nurses assessments, and were qualitatively compared to physicians’.

Results

Given the same AEs, nurses’ and physicians’ perception of the burden of AEs differed. While nurses generally perceived the overall burden of AEs to be only slightly worse compared to physicians (mean average VAS score of 5.44 versus 5.14), there was poor agreement in the perception of AEs that were in mild to severe range. The percent agreement for a moderate or worse AE was 64% with a Kappa of 0.34. Nurses also assigned higher severity scores to symptomatic AEs compared to physicians (p < 0.05), such as gastrointestinal (4.77 versus 4.14), hemorrhage (5.07 versus 4.14), and pain (5.17 versus 4.14).

Conclusions

These differences in the perception of burden of AEs can lead to different treatment decisions and symptom management strategies. Thus, having provider consistency, training, or a collaborative approach in follow-up care between nurses and physicians is important to ensure continuity in care delivery. Moreover, estimating overall burden from both physicians’ and nurses’ perspective, and comparing them may be useful for deciding when collaborations are warranted.
Literature
1.
go back to reference National Cancer Institute CTEP: Common Terminology Criteria for Adverse Events (CTCAE). 2009; Bethesda, Maryland, USA. National Cancer Institute CTEP: Common Terminology Criteria for Adverse Events (CTCAE). 2009; Bethesda, Maryland, USA.
2.
go back to reference Basch E. Towards patient-centered drug development in oncology. N Engl J Med. 2013;369:397–400.CrossRef Basch E. Towards patient-centered drug development in oncology. N Engl J Med. 2013;369:397–400.CrossRef
3.
go back to reference Basch E. Toward a patient-centered value framework in oncology. JAMA. 2016;315:2073–4.CrossRef Basch E. Toward a patient-centered value framework in oncology. JAMA. 2016;315:2073–4.CrossRef
4.
go back to reference Russell JS, Colevas AD. Adverse event monitoring in oncology clinial trials. Clinical Investigation. 2013;3:1157–65.CrossRef Russell JS, Colevas AD. Adverse event monitoring in oncology clinial trials. Clinical Investigation. 2013;3:1157–65.CrossRef
5.
go back to reference Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–9.CrossRef Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–9.CrossRef
6.
go back to reference Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016;13(5):319–25.CrossRef Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016;13(5):319–25.CrossRef
7.
go back to reference Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910–5.CrossRef Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910–5.CrossRef
8.
go back to reference Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol. 2004;22(17):3485–90.CrossRef Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol. 2004;22(17):3485–90.CrossRef
9.
go back to reference Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624–32.CrossRef Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624–32.CrossRef
10.
go back to reference Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects associated with Chemoradiotherapy for head and neck Cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517–23.CrossRef Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects associated with Chemoradiotherapy for head and neck Cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517–23.CrossRef
11.
go back to reference Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G. Clinician versus nurse symptom reporting using the National Cancer Institute-common terminology criteria for adverse events during chemotherapy: results of a comparison based on pateint’s self-reported questionanire. Ann Oncol. 2009;20:1929–35.CrossRef Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G. Clinician versus nurse symptom reporting using the National Cancer Institute-common terminology criteria for adverse events during chemotherapy: results of a comparison based on pateint’s self-reported questionanire. Ann Oncol. 2009;20:1929–35.CrossRef
12.
go back to reference Atkinson TM, Rogak LJ, Heon N, et al. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Research and Clin Oncol. 2017;143(4):735–743|.CrossRef Atkinson TM, Rogak LJ, Heon N, et al. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Research and Clin Oncol. 2017;143(4):735–743|.CrossRef
13.
go back to reference Lee SM, Hershman D, Miao J, Zhong X, Unger J, Cheung YK. Estimating global treatment toxicity burden from adverse event data. Cancer. 2018;124(4):858–64.CrossRef Lee SM, Hershman D, Miao J, Zhong X, Unger J, Cheung YK. Estimating global treatment toxicity burden from adverse event data. Cancer. 2018;124(4):858–64.CrossRef
14.
go back to reference Petrylak DP, Tangen CM, Hussain MHA, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and Estramustine compared with Mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.CrossRef Petrylak DP, Tangen CM, Hussain MHA, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and Estramustine compared with Mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.CrossRef
15.
go back to reference National Cancer Institute. CTEP. Common terminology criteria for adverse events version 2.0: Bethesda, Maryland. USA; 1998. National Cancer Institute. CTEP. Common terminology criteria for adverse events version 2.0: Bethesda, Maryland. USA; 1998.
16.
go back to reference Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley; 1981. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley; 1981.
17.
go back to reference Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1), 1–48.CrossRef Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1), 1–48.CrossRef
18.
go back to reference Bernhard J, Maibach R, Thurlimann B, et al. Patients’ estimation of overall treatment burden: why not ask the obvious? J Clin Oncol. 2002;20:65–72.PubMed Bernhard J, Maibach R, Thurlimann B, et al. Patients’ estimation of overall treatment burden: why not ask the obvious? J Clin Oncol. 2002;20:65–72.PubMed
Metadata
Title
A comparison of nurses’ and physicians’ perception of cancer treatment burden based on reported adverse events
Authors
Shing M. Lee
Jieling Miao
Ruby Wu
Joseph M. Unger
Ken Cheung
Dawn L. Hershman
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2019
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-019-1210-1

Other articles of this Issue 1/2019

Health and Quality of Life Outcomes 1/2019 Go to the issue